Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Dimerix Bioscience Pty Ltd
- Target Recruit Count
- 286
- Registration Number
- NCT05183646
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arizona Kidney Disease and Hypertension Center, Phoenix, Arizona, United States
Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Dimerix Bioscience Pty Ltd
- Target Recruit Count
- 8
- Registration Number
- NCT03649152
- Locations
- 🇦🇺
Renal Research, Gosford, New South Wales, Australia
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺Royal North Shore Hospital, St Leonards, New South Wales, Australia
Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Dimerix Bioscience Pty Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT03627715
- Locations
- 🇦🇺
Renal Research, Gosford, New South Wales, Australia
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺Royal North Shore Hospital, St Leonards, New South Wales, Australia